Moolec Science Stock Price, News & Analysis

Moolec Science SA (NASDAQ: MLEC) is a science-based food ingredient and life sciences company that focuses on producing animal proteins, nutritional oils, and other functional ingredients in plants and microbes. According to the company’s public statements, Moolec engineers plants and microbes to unlock scalable protein solutions for the global food system, integrating Molecular Farming with precision fermentation to combine the cost efficiency of crops with the functionality and nutrition of animal proteins. Its shares trade on the Nasdaq Capital Market under the ticker symbol MLEC.

Business focus and technology platforms

Moolec describes itself as an innovation-driven company that uses plant engineering and microbial technologies to create ingredients for the food and agriculture value chain. By integrating Molecular Farming and precision fermentation, the company aims to generate sustainable and commercially viable ingredients that can be produced at scale. Public disclosures state that Moolec’s diversified pipeline includes alternative proteins, bioactive compounds, nutritional oils, and biological inputs for regenerative agriculture.

The company reports that it has a significant intellectual property position, with more than 118 granted and pending patents across multiple technology platforms. This portfolio is intended to protect its Molecular Farming innovations, precision fermentation developments, and related ingredient technologies.

Molecular Farming and plant-based ingredient programs

Moolec’s ingredient programs include plant-based systems designed to express animal proteins and specialty lipids directly in crops. The company has disclosed a pipeline that historically included products such as TSP Valorasoy (a soy protein product), Glaso (a safflower oil with high levels of gamma-linolenic acid), SPC2 (a plant-based chymosin), and YEEA1 (an extract derived from a novel yeast biomass). In more recent communications, Moolec has emphasized its GLASO safflower platform and Piggy Sooy™ technology as key Molecular Farming assets.

The GLASO safflower platform is described as a proprietary crop enriched in gamma-linolenic acid (GLA), a specialty oil with nutritional and industrial applications. Moolec has reported regulatory approval in Argentina for its safflower GLASO technology for feed and food use, enabling expansion of this crop and supporting counter-season supply strategies. The company has also highlighted expansion of U.S. acreage dedicated to GLASO production to support revenue-generating activities and to build commercial inventory for customers in sectors such as pet food and human nutrition.

Piggy Sooy™ is described as a soybean plant engineered to express high levels of porcine hemeproteins in its seeds. Moolec has announced that it received a Notice of Allowance from the United States Patent and Trademark Office for this technology, covering the plants and seeds, the method used to develop them, and food compositions derived from them. The company reports that initial field trials demonstrated promising production yield and high animal protein content in the soluble protein fraction, and that U.S. regulatory authorities determined Piggy Sooy™ is not subject to certain plant pest regulations, which Moolec views as a milestone toward commercialization.

Precision fermentation and expanded life sciences platform

Through a strategic business combination with Bioceres Group Limited, Gentle Technologies Corp, and Nutrecon LLC, Moolec has described an expanded platform that spans food ingredients, ag-biologicals, precision fermentation, biomaterials, and R&D services. Following the closing of this business combination, Moolec stated that it would continue operating under the Moolec Science name as the parent company of an enlarged enterprise focused on sustainable solutions from molecule to ingredient.

As part of this transaction and subsequent integration, Moolec has highlighted the incorporation of Mycofood™ as a dedicated platform for fungal-based alternative proteins via precision fermentation, with applications under evaluation by food industry partners in North America and Europe. The company positions this fungal protein platform as complementary to its Molecular Farming programs, broadening its protein technology portfolio.

Ag-biologicals, regenerative agriculture, and biomaterials

In connection with the business combination, Moolec has indicated that it will offer upstream technologies for regenerative agriculture through brands associated with Bioceres Group, including biological inputs and climate-smart seeds under the Rizobacter®, ProFarm®, and HB4® brands. The company also references activities in emerging technologies for grain and biomass transformation, particularly in the biomaterials space, and new concepts in farm equipment that integrate material science, electric mobility, and autonomy, developed through subsidiaries of Gentle Tech and Bioceres Group.

Moolec has stated that its pipeline includes biological inputs for regenerative agriculture, aligning its ingredient and technology development with agricultural practices that seek to improve soil health and resource efficiency. These capabilities are supported by R&D and technical infrastructure platforms such as Agrality® and Synbio Powerlabs®, which Moolec describes as providing in-house R&D, contract development and manufacturing (CDMO), and regulatory capabilities to accelerate technology development and regulatory progression.

Operational footprint and markets

According to company disclosures, Moolec has operations spanning the United States, Europe, and South America. Earlier descriptions indicated that the company’s maximum revenues from operations were in Argentina. Subsequent press releases emphasize activities in the United States (including GLASO safflower campaigns and acreage expansion), regulatory approvals and potential counter-season supply strategies in Argentina, and commercial development and partnerships in North America and Europe for its protein and lipid ingredients.

Moolec has reported that it is engaging with organizations in the pet food and human nutrition industries, as well as wellness and performance brands in the nutrition and supplements market, particularly in relation to its GLASO safflower oil platform. The company has also indicated interest in high-concentration GLA softgel applications and access to established softgel distribution channels, positioning GLASO-derived ingredients for use in high-value nutritional markets.

Capital markets, listing status, and share structure

Moolec Science SA is publicly listed on the Nasdaq Capital Market under the symbol MLEC, with publicly traded warrants under the symbol MLECW. The company has disclosed several capital markets and listing-related developments.

Moolec has reported receiving determination letters from Nasdaq related to compliance with listing rules, including the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), the timely filing of its Annual Report on Form 20-F, and the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1). In each case, the company has publicly stated its intent to appeal or address these matters, including by requesting hearings before a Nasdaq Hearings Panel and by working to complete required filings.

To support compliance with Nasdaq listing standards, the company has implemented share structure changes. Moolec announced a reverse stock split (share consolidation) at a ratio of one-for-ten, reducing the number of issued and outstanding ordinary shares while maintaining the same par value per share. Later, Moolec’s shareholders approved, and the board implemented, a further share consolidation at a ratio of 15-for-1, consolidating every 15 ordinary shares of par value US$0.10 into one ordinary share of par value US$1.50. The company has stated that these consolidations do not affect its business or operations but are intended, among other purposes, to help regain compliance with Nasdaq’s minimum bid price requirement.

Moolec has also disclosed that it received a staff determination letter regarding the minimum stockholders’ equity requirement and that management expects to regain compliance through recognition of an accounting gain related to the derecognition of certain subsidiaries following bankruptcy proceedings. The company has indicated that this derecognition process is underway.

Corporate structure and jurisdiction

Moolec Science SA is described in SEC filings as a public limited liability company incorporated under the laws of the Cayman Islands, with principal executive offices in Grand Cayman, Cayman Islands. The company files reports with the U.S. Securities and Exchange Commission as a foreign private issuer, including Form 20-F annual reports and Form 6-K current reports.

Intellectual property and regulatory milestones

The company emphasizes its intellectual property portfolio, stating that it holds more than 118 granted and pending patents across multiple technology platforms. These include patents related to Molecular Farming innovations such as Piggy Sooy™ and GLASO™, as well as precision fermentation and related life sciences technologies.

Regulatory milestones disclosed by Moolec include the U.S. regulatory determination that Piggy Sooy™ does not present a plant pest risk difference from conventional soybeans under specific regulations, and feed and food approval in Argentina for its safflower GLASO technology. These regulatory decisions are presented by the company as important steps toward commercialization and expansion of its ingredient platforms.

Position within the food-tech and life sciences landscape

Through its combination of Molecular Farming, precision fermentation, ag-biologicals, and biomaterials initiatives, Moolec positions itself at the intersection of biotechnology and food production. Public communications describe the company as focusing on sustainable life sciences and food-tech innovation, with a seed-to-ingredient approach designed to transform aspects of food production and agricultural inputs.

Moolec’s activities span ingredient innovation (such as Piggy Sooy™, GLASO™, and Mycofood™), biological inputs and climate-smart seeds, and technical services through R&D and CDMO platforms. The company presents these elements as part of an integrated life science platform intended to support sustainable growth and long-term value creation within the food and agriculture sectors.

FAQs about Moolec Science SA (MLEC)

• What does Moolec Science SA do?
  Moolec Science SA focuses on engineering plants and microbes to produce animal proteins, nutritional oils, bioactive compounds, and biological inputs for regenerative agriculture. It integrates Molecular Farming and precision fermentation to develop scalable, commercially oriented ingredients for the global food system.
• How does Moolec generate value from its technologies?
  According to its public statements, Moolec develops ingredient platforms such as Piggy Sooy™, GLASO™, and Mycofood™, along with biological inputs and related technologies. These platforms are intended for use by food, nutrition, pet food, and agricultural industry partners, as well as for broader life sciences applications.
• What is Piggy Sooy™?
  Piggy Sooy™ is a proprietary soybean technology that Moolec describes as a plant engineered to express high levels of porcine hemeproteins in its seeds. The company has received a Notice of Allowance from the U.S. Patent and Trademark Office covering the plants, seeds, development methods, and related food compositions, and it reports that U.S. regulators have determined the plant is not subject to certain plant pest regulations.
• What is GLASO and how is it used?
  GLASO refers to Moolec’s safflower platform enriched in gamma-linolenic acid (GLA), a specialty oil with nutritional and industrial applications. The company has reported regulatory approval for GLASO technology in Argentina and expansion of safflower acreage in the United States to build inventory for customers in pet food, human nutrition, and nutrition and supplements markets.
• What is Mycofood™ in Moolec’s portfolio?
  Mycofood™ is described by Moolec as a dedicated platform for fungal-based alternative proteins produced via precision fermentation. The company states that its lead fungal protein ingredient is under commercial development, with applications being evaluated by food industry partners in North America and Europe.
• How did the business combination with Bioceres Group, Gentle Tech, and Nutrecon affect Moolec?
  Moolec has announced that, following a strategic business combination with Bioceres Group Limited, Gentle Technologies Corp, and Nutrecon LLC, it became the parent company of an expanded enterprise. This combination added capabilities in food ingredients, ag-biologicals, precision fermentation, biomaterials, and R&D services, while Moolec’s securities continue to trade on Nasdaq under the symbols MLEC and MLECW.
• Where does Moolec operate?
  The company reports operations spanning the United States, Europe, and South America. Public communications highlight U.S. safflower campaigns and acreage, regulatory approvals and potential supply strategies in Argentina, and commercial development activities with partners in North America and Europe.
• What is Moolec’s stock exchange listing?
  Moolec Science SA is publicly listed on the Nasdaq Capital Market under the ticker symbol MLEC. Its publicly traded warrants trade under the symbol MLECW. The company files reports with the U.S. Securities and Exchange Commission as a foreign private issuer.
• Has Moolec faced any Nasdaq compliance issues?
  Moolec has disclosed receiving Nasdaq determination and staff letters related to the minimum bid price requirement, timely filing of its Form 20-F, and minimum stockholders’ equity. The company has stated that it appealed certain determinations, requested hearings, and implemented share consolidations as part of its efforts to address these listing requirements.
• What share consolidations has Moolec implemented?
  The company has announced a reverse stock split at a one-for-ten ratio and, later, a share consolidation at a 15-for-1 ratio. These actions reduced the number of issued and outstanding ordinary shares and were described as not affecting the company’s business or operations, while supporting efforts to comply with Nasdaq’s continued listing standards.
• What role do patents play in Moolec’s strategy?
  Moolec highlights its intellectual property portfolio, stating that it has more than 118 granted and pending patents across its technology platforms. Patents such as the one covering Piggy Sooy™ are presented as key assets that protect its Molecular Farming and related innovations and support long-term commercialization plans.
• Is Moolec still an active company?
  Based on its recent press releases and SEC filings, Moolec continues to describe ongoing operations, technology development, regulatory milestones, and listing-related actions. There is no indication in the provided materials that the company has been delisted from Nasdaq or has ceased operations.